Investigational drug IBI355 for moderate-to-severe Sjögren's disease
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of Sjögren's disease (per official criteria).
- Your Sjögren's diagnosis should have been made less than 7.5 years ago.
- Your blood test must show a specific antibody called anti-Ro/SSA.
- Your disease must be active (at least moderate in severity) based on a standard scoring system.
- If you are on background treatments (like hydroxychloroquine or methotrexate), they must be at a stable dose for at least 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This trial tests an experimental medicine (BMS-986553) for people with autoimmune diseases that have not improved with other treatments. It aims to see if the drug is safe and helpful for conditions like lupus, myositis, scleroderma, rheumatoid arthritis, and Sjögren's disease.
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
Hear when a new Sjögren's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.